Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00955487 · ClinicalTrials.gov registry record · Phase 2
Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT00955487 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 124 participants.
The verdict
NCT00955487, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
Bronchopulmonary dysplasia (BPD) is a serious lung condition that affects premature newborns. The condition involves abnormal development of lung tissue and is characterized by inflammation and scarring in the lungs. Treatment with inhaled nitric oxide (iNO) may reduce the incidence of BPD and another commonly associated condition called pulmonary hypertension, which is high blood pressure in the vessels carrying blood to the lungs.. This study will determine if early treatment with low-dose iNO reduces the incidence of BPD, pulmonary hypertension, and death in premature newborns.
Interventions
- DRUG Inhaled Nitric Oxide (iNO)
- DRUG Nitrogen (placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2007-01 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00955487
The ClinicalTrials.gov registry entry for NCT00955487 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Inhaled Nitric Oxide (iNO) is the first listed.
NCT00955487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00955487 about?
NCT00955487 is a clinical study titled "Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns". Bronchopulmonary dysplasia (BPD) is a serious lung condition that affects premature newborns. The condition involves abnormal development of lung tissue and is characterized by inflammation and scarring in the lungs. Treatment with inhaled nitric oxide (iNO) may reduce the incidence of BPD and anoth...
What is the current status of trial NCT00955487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2007-01. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00955487?
The interventions under investigation include: Inhaled Nitric Oxide (iNO) (DRUG), Nitrogen (placebo) (DRUG).
Who is sponsoring clinical trial NCT00955487?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.